8-K: Neuronetics Reports Strong Q4 2025 Revenue, Appoints New CEO

Neuronetics announced robust fourth-quarter and full-year 2025 financial results, driven by the Greenbrook acquisition, alongside the appointment of Daniel L. Reuvers as its new President and CEO.

Summary

• Total revenue for Q4 2025 was $41.8 million, an 86% increase as reported and 23% on an adjusted pro forma basis compared to Q4 2024.
• Full-year 2025 total revenue reached $149.2 million, up 99% as reported and 15% on an adjusted pro forma basis compared to full-year 2024.
• Greenbrook clinic revenue for Q4 2025 was $23.5 million, a 428% increase as reported and 37% on an adjusted pro forma basis compared to Q4 2024.
• Greenbrook clinic revenue for full-year 2025 was $87.0 million, an 1,857% increase as reported and 28% on an adjusted pro forma basis compared to full-year 2024.
• U.S. NeuroStar Advanced Therapy System revenue for Q4 2025 was $4.4 million, an increase of 15%, with 49 systems shipped.
• U.S. NeuroStar Advanced Therapy System revenue for full-year 2025 was $14.3 million, a decrease of 7%, with 161 systems shipped.
• Net loss for Q4 2025 was $(7.2) million, or $(0.10) per share.
• Net loss for full-year 2025 was $(39.1) million, or $(0.59) per share.
• Cash provided by operations in Q4 2025 was $0.9 million, indicating continued cash management improvement.
• Total cash (cash and cash equivalents plus restricted cash) as of December 31, 2025, was $34.1 million.
• Daniel L. Reuvers was appointed President and Chief Executive Officer, effective March 23, 2026, bringing over 30 years of medical device leadership experience.
• The company amended its agreement with Perceptive Advisors LLC in March 2026, reducing total outstanding debt obligation and ongoing interest expense, including a one-time principal payment of $5.0 million.
• Neuronetics is advancing its collaboration with Compass Pathways on COMP360 psilocybin for Treatment Resistant Depression, with potential for an FDA decision by year-end 2026.
• TRICARE West expanded coverage for transcranial magnetic stimulation (TMS) therapy, including NeuroStar Advanced Therapy, to adolescents aged 15 and older diagnosed with depression.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting strong revenue growth driven by strategic acquisitions and improved cash management, alongside a significant leadership appointment and promising collaborations, despite ongoing net losses and gross margin compression.

Positives

• Total revenue increased significantly by 86% in Q4 2025 and 99% for the full year 2025 as reported, primarily driven by the Greenbrook acquisition.
• Achieved positive operating cash flow of $0.9 million in Q4 2025, demonstrating improved operational discipline and cash collection.
• The appointment of Daniel L. Reuvers as President and CEO brings a seasoned medical device leader with a proven track record of growing revenue, earnings, and cash flow.
• Advancing collaboration with Compass Pathways on COMP360 psilocybin offers a potential transformational new treatment for treatment-resistant depression, broadening the company's platform.
• Expanded TRICARE West coverage for TMS therapy to adolescents aged 15 and older increases market access and addresses a critical patient population.
• Reached a milestone of over 237,000 global patients treated with over 8 million treatment sessions.
• Amended debt agreement with Perceptive Advisors LLC reduces total outstanding debt obligation and ongoing interest expense, improving financial flexibility.

Negatives

• Gross margin decreased to 52.0% in Q4 2025 (from 66.2% in Q4 2024) and 48.5% for full-year 2025 (from 72.3% in FY 2024), primarily due to the inclusion of Greenbrook's clinic business.
• U.S. NeuroStar Advanced Therapy System revenue decreased 7% for the full year 2025, despite a Q4 increase.
• U.S. treatment session revenue decreased 4% in Q4 2025 and 15% for the full year 2025 as reported, though it increased on a pro forma basis.
• The company reported continued net losses of $(7.2) million in Q4 2025 and $(39.1) million for full-year 2025.
• Full-year 2026 operating cash flow guidance remains negative, projected between $(13) million and $(17) million.

Risks

• The effect of the transaction with Greenbrook TMS Inc. on business relationships, operating results, and business generally.
• Ability to execute business strategy effectively.
• Ability to achieve or sustain profitable operations due to a history of losses.
• Reliance on the sale and usage of NeuroStar Advanced Therapy System to generate revenues.
• The scale and efficacy of the salesforce.
• Ability to retain talent within the organization.
• Availability of coverage and reimbursement from third-party payors for treatments using products.
• Physician and patient demand for treatments using products.
• Developments in respect of competing technologies and therapies for the indications that products treat.
• Potential for product defects.
• Ability to obtain and maintain intellectual property protection for technology.
• Developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications.
• Developments in regulation in the U.S. and other applicable jurisdictions.
• Potential effects of evolving and/or extensive government regulation.
• The terms of the credit facility.
• Ability to successfully roll-out the Better Me Provider Program on the planned timeline.
• Self-sustainability and existing cash balances.

Future Outlook

For the first quarter of 2026, the company expects total worldwide revenue between $33.0 million and $35.0 million. For the full year 2026, Neuronetics anticipates total revenue between $160 million and $166 million, gross margin between 47% and 49%, and operating expenses between $100 million and $105 million (including approximately $8.5 million of non-cash stock-based compensation). Operating cash flow for full-year 2026 is expected to be between $(13) million and $(17) million. The company projects a reduction in operating expenses in the second half of 2026, with annualized operating expenses less than $100 million by Q4 2026, and expects operating cash flow to improve significantly throughout the year.

Management Comments

• "A year ago, we set out to build a vertically integrated mental health company, and I am proud of what this team delivered. Our Greenbrook clinics drove significant revenue growth as operational and commercial initiatives took hold across the network, and our NeuroStar business finished the year with solid momentum in both system sales and treatment utilization." Keith Sullivan, President and Chief Executive Officer of Neuronetics.
• "We exited the year with positive operating cash flow in the fourth quarter, a direct result of this team's focus on growth, operational discipline, and cash collection throughout 2025." Keith Sullivan.
• "The platform we have built is now opening doors that neither company could pursue alone. Our collaboration with Compass Pathways on COMP360 psilocybin is a great example." Keith Sullivan.
• "I'm pleased to welcome Dan Reuvers as our next President and CEO, and I'm confident his proven leadership in building and scaling commercial healthcare businesses makes him the right person to lead Neuronetics in its next chapter of growth." Keith Sullivan.
• "I am honored and excited to be joining the Neuronetics team. The Company's leading TMS treatment platform, in conjunction with our national care delivery network provides a great foundation to build upon and drive profitable growth." Daniel L. Reuvers, incoming President and Chief Executive Officer.
• "There are millions of people suffering from depression who remain underserved by existing treatments. I am pleased to join the talented Neuronetics team and believe we are uniquely positioned to expand access to treatments that can restore hope for patients and their families." Daniel L. Reuvers.
• "The Phase 3 results for COMP360 are an exciting development in this space, and our collaboration with Compass gives us an exciting potential path to offer another differentiated treatment across our national clinic network." Dr. Geoffrey Grammer, Chief Medical Officer of Neuronetics.

Industry Context

StockSavvy.ai notes that Neuronetics is strategically positioning itself as a vertically integrated mental health company, combining its NeuroStar TMS device leadership with Greenbrook's extensive clinic network. This integration allows for broader patient access and the potential to introduce new modalities like COMP360 psilocybin, aligning with a growing trend in mental healthcare towards diversified, clinic-based treatment options beyond traditional pharmaceuticals. The expansion of TRICARE coverage for adolescents also reflects a broader industry recognition of non-pharmacological interventions for mental health, potentially expanding the addressable market for TMS therapy.

Comparison to Industry Standards

• NeuroStar Advanced Therapy is positioned as the leading TMS treatment for Major Depressive Disorder (MDD) in adults, supported by over 8 million treatments delivered and the largest clinical data set of any TMS treatment system for depression.
• NeuroStar is the first FDA-cleared TMS treatment for adolescent depression, indicating a pioneering role in this specific market segment.
• Daniel L. Reuvers, the incoming CEO, has a strong track record, having grown Tactile Medical's revenue from $187 million to approximately $300 million while delivering record earnings and cash flow, demonstrating his capability in scaling medical technology businesses, which is a positive benchmark for future performance.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth, improved cash flow, experienced new leadership, and strategic expansion into new treatments and markets. However, continued net losses and gross margin pressure remain a concern.
• Employees: The appointment of a new CEO may lead to strategic shifts and organizational adjustments; ongoing efficiency initiatives could impact roles.
• Customers (Clinics/Providers): Enhanced support through the Better Me Provider Program, expanded SPRAVATO offerings, and centralized services aim to improve practice success and patient flow.
• Patients: Increased access to NeuroStar TMS therapy, particularly for adolescents, and potential future access to new treatments like COMP360 psilocybin, offering more options for neurohealth conditions.
• Creditors: The amended debt agreement with Perceptive Advisors LLC, including a principal payment and covenant adjustments, improves the company's financial stability and reduces ongoing interest expense.

Next Steps

• Daniel L. Reuvers is expected to commence employment as President and Chief Executive Officer on March 23, 2026.
• Compass Pathways plans to submit an NDA for COMP360 psilocybin, with a potential FDA decision by year-end 2026.
• The company anticipates a reduction in operating expenses in the second half of 2026 due to ongoing efficiency initiatives.
• Operating expenses are projected to be less than $100 million on an annualized basis by the fourth quarter of 2026.
• Operating cash flow is expected to improve significantly throughout 2026, driven by revenue growth, cost reduction, and working capital improvements.
• Continued focus on execution, profitable product diversification, and expansion across the 93 Greenbrook clinics.
• Drive growth in clinics through enhanced Regional Account Manager (RAM) clinic engagement, automated referral systems, and optimized digital/Direct-to-Consumer (DTC) targeting.
• Further expansion of SPRAVATO offerings to all suitable locations using a Buy & Bill model.
• Standardize operational excellence across the network through comprehensive training, enhanced practice capabilities, and centralized services.
• Expand referral networks for over 420 Better Me Provider (BMP) Clinics, with approximately 100 additional sites committed to the program.
• Continued implementation of fully optimized digital/DTC investment benefiting patients and BMP practices.
• Establish a centralized call center to help BMP providers manage patient inquiries more efficiently.

Key Dates

Recommendation

The company demonstrates strong top-line growth, particularly from the Greenbrook acquisition, and has achieved positive operating cash flow in the latest quarter, signaling improved operational efficiency. The appointment of a seasoned CEO with a track record of scaling medical device businesses, coupled with strategic collaborations and expanded market access (TRICARE for adolescents), positions Neuronetics for continued growth and potential profitability despite current net losses. The debt restructuring also strengthens the balance sheet, making it an attractive investment for long-term growth.

Keywords

Neuronetics, STIM, NeuroStar, TMS therapy, Transcranial Magnetic Stimulation, Greenbrook TMS, mental health, depression treatment, medical technology, financial results, CEO appointment, COMP360 psilocybin, TRICARE coverage, Q4 2025 earnings, full year 2025 results, healthcare, neurohealth, medical device